Reducing transmission of SARS-CoV-2 with intranasal prophylaxis

EBioMedicine. 2021 Jan:63:103170. doi: 10.1016/j.ebiom.2020.103170. Epub 2020 Dec 16.
No abstract available

MeSH terms

  • Administration, Intranasal
  • Animals
  • Antiviral Agents / therapeutic use*
  • COVID-19 / prevention & control
  • COVID-19 / therapy
  • COVID-19 / transmission
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • Ferrets
  • Humans
  • Immunization, Passive / methods
  • Lipopeptides / chemistry
  • Lipopeptides / therapeutic use
  • Mice
  • SARS-CoV-2 / drug effects*
  • Toll-Like Receptor 2 / agonists

Substances

  • Antiviral Agents
  • Lipopeptides
  • S-(2,3-bis(palmitoyloxy)propyl)cysteine
  • TLR2 protein, human
  • Toll-Like Receptor 2